Next Generation Immunotherapies Market Report 2026

The next generation immunotherapies market size has grown rapidly in recent years. It will grow from $150.12 billion in 2025 to $168.33 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to rising global cancer prevalence, early success of immune checkpoint inhibitors, increased oncology r&d investments, regulatory approvals of monoclonal antibodies, growing awareness of immuno-oncology therapies.

The next generation immunotherapies market size is expected to see rapid growth in the next few years. It will grow to $262.82 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to advancements in next-generation antibody engineering, expanding applications beyond oncology, increasing approval of adc-based therapies, growth in biomarker-driven treatment selection, rising demand for durable and long-lasting therapies. Major trends in the forecast period include expansion of combination immunotherapy regimens, growth in personalized cancer vaccines, rising adoption of bispecific antibodies, increasing focus on reducing immune-related adverse events, accelerated clinical trial activity in solid tumors.

The rising prevalence of cancer is expected to drive the growth of the next-generation immunotherapies market in the coming years. Cancer refers to a group of diseases marked by the uncontrolled growth and spread of abnormal cells within the body. The increasing burden of cancer is attributed to factors such as aging populations, lifestyle changes, environmental exposure, and advancements in detection and diagnostic techniques. Next-generation immunotherapies offer advanced, targeted treatment options that strengthen the body’s immune response against cancer, delivering improved effectiveness, longer-lasting responses, and more personalized care. For example, in July 2024, projections released by Cancer Research UK, a UK-based cancer charity, indicated that cancer incidence rates in the United Kingdom are expected to rise for most cancer types between 2023-2025 and 2038-2040, with increases ranging from under 1% for breast cancer to as high as 50% for eye cancer. In contrast, a smaller number of cancers are projected to decline, with reductions ranging from 2% for lung cancer to 27% for mesothelioma. As a result, the growing prevalence of cancer is fueling the expansion of the next-generation immunotherapies market.

Major companies operating in the next-generation immunotherapies market are concentrating on the development of innovative treatments, such as CAR T-cell therapy, to address cancers, autoimmune disorders, and infectious diseases. CAR T-cell therapy is a form of immunotherapy in which a patient’s T cells, a key component of the immune system, are genetically engineered to express chimeric antigen receptors (CARs) that specifically recognize and attack disease-causing cells. For instance, in January 2025, Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, launched Qartemi, India’s first CAR T-cell therapy. Designed for adult B-cell non-Hodgkin lymphoma, this therapy modifies a patient’s immune cells to precisely target and eliminate cancer cells, providing a highly personalized and effective treatment option. It offers renewed hope for patients who have not responded to conventional therapies, while also being more affordable compared to similar global alternatives.

In September 2023, Coherus BioSciences Inc., a U.S.-based biopharmaceutical company, completed the acquisition of Surface Oncology Inc. for an undisclosed amount. Through this acquisition, Coherus BioSciences aims to strengthen its immuno-oncology portfolio by incorporating novel therapies that target the tumor microenvironment to improve cancer treatment outcomes. Surface Oncology Inc. is a U.S.-based immuno-oncology company focused on developing next-generation immunotherapies designed to modulate and target the tumor microenvironment.

Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.

North America was the largest region in the next-generation immunotherapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next generation immunotherapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created both cost pressures and strategic shifts in the next generation immunotherapies market by increasing prices of imported biologics, active pharmaceutical ingredients, and specialized manufacturing equipment. These impacts are most pronounced across monoclonal antibodies, ADCs, and immune checkpoint inhibitor segments, particularly affecting regions dependent on cross-border biopharmaceutical supply chains such as North America, Europe, and parts of Asia-Pacific. Higher tariffs have contributed to increased treatment costs and delayed commercialization timelines, especially for hospital and clinical pharmacy distribution channels. However, tariffs have also encouraged local manufacturing, regional supply chain resilience, and increased domestic investments in biologics production capabilities.

The next generation immunotherapies market research report is one of a series of new reports that provides next generation immunotherapies market statistics, including next generation immunotherapies industry global market size, regional shares, competitors with a next generation immunotherapies market share, detailed next generation immunotherapies market segments, market trends and opportunities, and any further data you may need to thrive in the next generation immunotherapies industry. This next generation immunotherapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Next-generation immunotherapies are advanced treatment approaches developed to strengthen the body’s immune system in combating diseases, particularly cancer, with greater precision, effectiveness, and safety. These therapies extend beyond conventional immune-based treatments by utilizing cutting-edge technologies and are intended to address the limitations of earlier immunotherapies, minimize side effects, and provide durable immune responses.

The primary drug classes in next-generation immunotherapies include monoclonal antibodies, antibody-drug conjugates (ADCs), angiotensin-converting enzyme (ACE) inhibitors, and immune checkpoint inhibitors. Monoclonal antibodies are laboratory-engineered proteins created to selectively target specific antigens, thereby enhancing immune activity and therapeutic efficacy. These drugs are delivered through multiple administration routes, including intravenous, parenteral, intratumoral, subcutaneous, and oral, and are distributed via various channels such as hospital pharmacies, clinical pharmacies, and other distribution outlets.

The next-generation immunotherapies market consists of revenues earned by entities providing services such as cell therapy manufacturing services, gene editing and engineering services, consulting services, diagnostic services, and distribution and logistics. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation immunotherapies market also includes sales of CAR-T cell therapies, natural killer (NK) cell therapies, combination therapies, and checkpoint inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.